Physician profile
Anand Joshi
NPI 1992716237
$3,657.13
in general payments reported to CMS, 2019-2025
20 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 89% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $214 · 2021: $449 · 2022: $840 · 2023: $394 · 2024: $360 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Travel and Lodging: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.90 |
| Travel and Lodging | $680.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $813.16 | 2023-2025 | |
| Boston Scientific Corporation | $570.87 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Spr Therapeutics, INC | $458.50 | 2022-2024 | Sprint Pns System |
| Trice Medical, INC. | $323.96 | 2022 | |
| Nevro Corp. | $314.26 | 2019-2022 | |
| Medtronic, INC. | $239.75 | 2022-2025 | Primeadvanced Surescan, Vanta Adaptivestim, Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $189.95 | 2019-2021 | |
| Abbott Laboratories | $149.66 | 2019-2025 | Proclaim |
| Hydrocision, INC. | $141.36 | 2021-2024 | Tenjet |
| Novo Nordisk INC | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.83 | 2019 | |
| Relievant Medsystems, INC. | $58.50 | 2022 | |
| Scilex Pharmaceuticals INC. | $50.06 | 2019-2023 | Ztlido |
| Stryker Corporation | $43.80 | 2019 | |
| Abbvie INC. | $35.30 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $23.12 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Fidia Pharma USA INC. | $17.61 | 2024 | Hymovis |
| Collegium Pharmaceutical, INC. | $14.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.53 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.